After a phase 3 push the livmoniplimab plan falters.
ApexOnco Front Page
Recent articles
The company discontinues one of its two KRAS G12D degraders.
Giredestrant will soon become the first oral SERD to yield first-line data.
The company hits an FDA-mandated enrolment target, but only in follicular lymphoma.
The company is starting a phase 3 trial of sacituzumab tirumotecan in first-line TNBC.
But this adds another complexity, and has camizestrant really scored a first-line win?
The Met x Met ADC REGN5093-M114 has been discontinued, but a Met x Met bispecific antibody remains.
A key pivotal study of bemarituzumab will read out shortly.
